Shahzad Hasan

Dr. Shahzad Hasan is a Senior Research Fellow at the Department of Pharmacy, School of Applied Sciences, University of Huddersfield. He also holds a conjoint Senior Lecturer position at the University of Newcastle, Australia. His expertise spans clinical pharmacy research, pharmacoepidemiology, chronic disease epidemiology, and evidence synthesis, with a focus on safe medication use and public health. Hasan has authored over 250 peer-reviewed publications and is recognized as a top researcher in the UK. He leads evidence synthesis efforts for optimizing medication use during pandemics, particularly during the global response to the SARS-CoV-2 virus.

Education:

• Pharmacy degree (BPharm), University of Karachi
• MSc in Clinical Pharmacy, Universiti Sains Malaysia
• PhD in Quality Use of Medicine and Pharmacoepidemiology, University of Queensland, Australia

Research Interests: Hasan's work emphasizes evidence-based approaches to drug safety, including systematic reviews and meta-analyses. His contributions to understanding chronic disease burdens, such as diabetes and mental health linkages, are supported by collaborations with global networks like the Global Burden of Disease (GBD) initiative. His recent focus on optimizing anticoagulant strategies in critical care and addressing post-COVID-19 complications underscores his commitment to translational research.

Editorial Roles: Associate Editor of Journal of Medical Virology, Guest Editor for Pharmaceuticals and Frontiers in Pharmacology, and editorial board member for several journals. He actively reviews for high-impact journals like The Lancet Haematology and BMJ Open.

Awards:

• ISPOR Excellent Research Article Award (2020-21)
• Fellow of the Higher Education Academy
• IPRS/UQ Centennial Scholarship (Australia)

Advising & Grants: Supervises PhD students and reviews grants for organizations like Diabetes UK. His research has been featured in media discussions on safe medication use during the pandemic.

Labs/Teams: Leads the evidence synthesis group at Huddersfield, collaborating globally on pandemic-related drug efficacy studies and chronic disease epidemiology.